Advancing Cell Therapy Development
Cancer cell therapy holds the promise to revolutionize the options for patients refractory to conventional treatments including immune checkpoint inhibitors. While CAR-T and other cell therapies have shown remarkable outcomes in hematologic malignancies, their efficacy in solid tumors has proved to be more challenging.
Only 1 cell therapy has been approved for solid tumors and a mere 14% of cell therapies advance from phase II trials. This is because solid tumors pose unique challenges for cell therapy migration, persistence, and exhaustion that limit efficacy.
The answers to cell therapy translational research can be found in complex biological models that bring together the human tumor microenvironment and dynamic culture systems.
Assess Migration and Efficacy in a Complex Tumor Environment
Xsphera’s human tissue platform recapitulates the complexity of each patient’s solid tumor environment and enables controlled studies to assess peripheral cell therapy migration through the ECM and subsequent tumor cell killing.
Select the Best Candidate Before Clinical Trials
Use the Xsphera Platform to evaluate multiple cell therapy candidates within a single patient and across diverse patients.
Incorporate into Your Cell Therapy Development Process
Lead Optimization
Engineer candidates with maximized efficacy
Candidate Selection
Select for better cell therapy properties
Candidate Profiling
Prepare better clinical trials through patient stratification
Contact Our Team to Plan Your Study
Our team is here to support your team with study design, execution and analysis. We seamlessly integrate as an extension of your team, providing collaboration and transparency throughout the process.
© 2023 Xsphera Biosciences
6 Tide Street
Boston, MA, 02210 — ALL RIGHTS RESERVED